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1571 ABSTRACT 
A + strand RNA viral transformation of host organisms with 
foreign RNA, and expression of said foreign RNA. The 
foreign RNA is inserted into an infective RNA viral segment 
containing replication elements, and allowed to infect the 
host organism. The invention is exemplified utilizing brome 
mosaic RNA modified to contain a gene codting for 
chloramphenicol acetyl transferase (CAT) in the transfor- 
mation of barley protoplasts. 
27 Claims, 6 Drawing Sheets 
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RNA TRANSFORMATION VECTOR modified RNA is used to transfer a desired RNA segment 
into a targeted host cell and to replicate that segment and 
This application is a continuation, of application Ser- NO. express its function within the host cell. A virus known to be 
071916,799, filed Jul. 17, 1992, now abandoned, which is a representative of the common replication functions of (+I 
continuation of application Ser. No. 071368,939, filed Jun. 5 strand RNA viruses was the present 
19, 1989, now abandoned, which is a continuation of appli- invention herein. 
cation Ser. No. 061709,181, filed Mar. 7, 1985, now aban- Brome mosaic virus (BMV) is one member of a class of 
doned. plant viruses characterized by a multipartite RNA genome. 
The genetic material of the virus is RNA, and the total 
FIELD OF THE INVENTION lo genetic information required for replication and productive infection is divided into more than one discrete RNA mol- 
This invention relates to the field of plant viruses, more ecule. The class, tenned multipartite RNA viruses herein, 
particularly to (+) strand mA viruses of plants,animals and includes, besides BMV, such viruses as alfalfa mosaic virus 
bacteria, and to modifications, made according to the teach- (AMV), mosaic virus* 'Owpea mosaic virus, ings herein, which pennit insertion of an exogenous RNA l5 cucumber mosaic virus, and many others. Virus particles are 
segment into the viral genome, ne inserted segment can generally com~osed of RNA enca~sidated by a protein coat. 
then be introduced into a host cell in order to modify the cell, The separate RNA molecules which comprise the 
either genotypically or phenotypically. The invention is genome a given virus are enca~sidated in 
exemplified by modifications of an RNA plant virus, brome separate virus particles, each of which has the same protein 
mosaic virus (BMV), which is infective for monocots. 20 composition. Infection of a host plant cell occurs when a 
virus  article containing each of the RNA comuonents of the 
BACKGROUND AND PFUOR ART 
" 
viral genome has infected the cell, for example by exposing 
a plant to a virus preparation containing a mixture of all 
- - 
RNA viruses whose genome is of a single RNA necessary viral components. Infection may also be achieved 
strand capable of replication in the cytoplasm of a host by 25 by exposing a plant cell or protoplast to a mixture of the 
direct RNA replication are widespread, many varieties of RNA components. A subclass of the multipartite RNA 
which are known infect animals, plants and viruses (termed subclass I herein) requires coat protein in 
bacteria. such viruses are sometimes termed =(+I addition to viral RNA for replication and productive infec- 
RNA virusesm since the infective RNA strand, that normally tion. AMV is an example of a subclass I multipartite virus. 
found encapsidated in the virus particle, is a messenger- 30 h o t h e r  subclass (termed subclass II herein) does not 
sense strand, capable of being directly translated, and also require coat protein, the component RNAs being both net- 
capable of being replicated the proper conditions by a essary and sufficient for replication and productive infection. 
direct process of RNA replication. viruses belonging to this BMV belongs to subclass II. The BMV genome is divided 
group include, but are not limited to, the picornaviruses, the among three messenger-sense RNAs of 3.29 2.8 and 2.1 
RNA bacteriophages, the comoviruses, and various single 35 kilobases (Ahlquist, P. et al. (1981) J. Mol. Biol. 153,23; 
component and multicomponent RNA viruses of plants. A Ahlquist, P., et al. (1984) J. Mol. Biol. 172,369). The term 
listing of such viruses would include polio virus, "messenger-sense" denotes that the viral RNAs can be 
sindbis virus, QP bacteriophage, tobacco mosaic virus, bar- directly translated to yield viral proteins, without the need 
ley stripe mosaic virus, cow pea mosaic virus, cucumber for an intervening 
mosaic virus, alfalfa mosaic virus and brome mosaic virus. 40 Complete cDNA copies of each of the three BMV genetic 
In some cases, the entire virus genome is contained within components have been cloned in a general transcription 
a single RNA molecule, while in other cases, most notably vector, pPM1, described by Ahlquist, P. and Janda, M. 
the multicomponent RNA plant viruses, the total genome of (1984) Mol. Cell Biol. 4,2876. Three plasmids have been 
the virus consists of two or more distinct RNA segments, selected, pBlPM18, pB2PM25 and pB3PM1 containing, 
each separately encapsidated. (For general review, see Gen- 45 respectively, cDNA copies of BMV-RNA1, BMV-RNA2 
era1 Virology, S. Luria and J. Darnell; Plant Emlogy 2nd and BMV-RNA3. The three plasmids constitute, as a set, the 
ed., R. E. F. Matthews, Academic Press (1981); and for a complete BMV genome. 
general review of (+) strand RNA replication, see Davies DNA from each of the three BMV cDNA-containing 
and Hull (1982) J. Gen. Viral. 61,l). Within the group there plasmids can be cleaved at a unique EcoRI site. The linear 
are wide variations in capsid morpholog~~ coat proteins, 50 DNA thus produced can be transcribed in vitro in a reaction 
genetic organization and genome size. catalyzed by RNA polymerase. A modified Ir. P, promoter in 
Despite the well-documented diversity, recent studies the transcription vector, pPM1, allows RNA synthesis to 
have shown striking similarities between the proteins which initiate exactly at the 5' terminus of each BMV sequence, 
function in RNA replication. Sequence homologies have and transcription continues to the end of the DNA template, 
been reported between the cowpea mosaic virus, poliovirus 55 adding 6-7 nonviral nucleotides at the 3' ends of the 
and foot-and-mouth disease virus (Franssen, H. (1984) transcripts. When transcription is carried out in the presence 
EMBO Journal 3,855), between non-structural proteins of a synthetic cap structure, m7Gppp~,  as described by 
encoded by alfalfa mosaic virus, brome mosaic virus and Contreras, R., et al. (1982) Nucleic Acids Res. 10,6353, 
tobacco mosaic virus, Haseloff, J. et al. (1984), Proc. Nat. RNA transcripts are produced with the same capped 5' ends 
Acad. Sci. USA 81, 4358, and between the same proteins 60 as authentic BMV RNAs. These RNAs are active messen- 
and proteins encoded by sindbis virus, Ahlquist, P. et al. gers in in vitro translation systems and direct production of 
(1985) J. Virol. 53, 536. Evidence of such substantial proteins with the same electrophoretic mobilities as those 
homology in proteins related to the replication functions translated from authentic BMV RNAs. 
indicate-that ;he viruses share mechanistic similarities in 
their replication strategies and may actually be evolution- 65 SUMMARY OF THE INVENTION 
arily related. In the present invention, modifications to the For the sake of brevity, the term "RNA virus" is used 
genomic RNA of a (+) strand RNA virus are disclosed. The herein to mean (+) strand replicating RNA viruses. 
5,500,360 
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The invention is based on the discovery that an RNA of the cell. Such a function could be a coding function, trans- 
the genome of an RNA virus can be modified to include an lated within the cell to yield a desired peptide or protein, or 
exogenous RNA segment and that the modified RNA can be it could be a regulatory function, increasing, decreasing, 
introduced into a host cell, replicated therein and can express turning on or off the expression of certain genes within the 
the exogenous RN.4 segment. The recipient cell is thereby 5 cell. Any function which a segment of RNA is capable of 
phenotypically transfmned and may contribute to a gene- providing can, in principle, be expressed within the cell. The 
typically transformed organism, as well. P h e n o t ~ ~ i c a l l ~  exogenous RNA segment thus expressed confers a new 
transformed cells can be modified in vivo, in planta, in tissue phenotypic trait to the transformed organism, plant, cells, 
culture, in cell culture or in the form of protoplasts. The protoplasts or tissues. 
exemplified embodiment of the invention is useful for 10 ne invention is exemplified herein by the modification of 
producing P ~ ~ ~ ~ ~ Y P ~ ~ ~ ~ Y  transformed plants under BMV RNA to a structural gene encoding chloram- 
conditions or greenhouse growth. Traits desirable for intro- phenicol acetyl wansferase (CAT) and the phenotypic modi- 
duction in this manner but are limited pest fication of barley protoplasts therewith, yielding protoplasts 
resistance, pathogen resistance, herbicide tolerance or resis- synthesizing CAT. The data presented herein are believed to 
tance, modified growth habit and Illodified char- 15 represent the first instance of phenotypic modification of a 
acteristics, such as the production of commercially useful. cell by means of a modified RNA of an RNA virus. 
peptides or pharmaceuticals in plants. The modifications can 
be applied at any time during the growth cycle, depending 
on the need for the trait. For example, resistance to a pest BRIEF DESCRIPTION OF THE DRAWINGS 
could be conferred only if the crop were at risk for that pest, 
and at the time when the crop was most likely to be affected 
by the pest. Other traits can be used to enhance secondary 
properties, for example to increase the protein content of 
po$-harvest forage. Any plant variety susceptible to infec- 
tion by a multipartite RNA virus can be phenotypically 
transformed. The choice of virus and the details of modifi- 
cation will be matters of choice depending on parameters 
known and understood by those of ordinary skill in the art. 
Other uses for cells and organisms phenotypically or geno- 
typically modified by means of a modified RNA derived 
from an RNA virus will be readily apparent to those skilled 
in the art, given a wide range of RNA viruses to modify and 
a wide range of susceptible host cell types. Other uses for 
transformed animal cells, bacterial cells and the like can be 
readily envisioned. For example, bacterial cells susceptible 
to QP phage can be grown in culture to desired cell density, 
infected with a modified QP phage carrying a desired gene 
and thereby caused to express large quantities of a desired 
protein within a short time period. 
Generally, the steps of a process for phenotypically trans- 
forming a cell or organism are: forming a full-length cDNA 
transcript of the virus RNA, or of each RNA component if 
the RNA virus is multipartite; cloning each cDNA in a 
transcription vector; modifying the cDNA of at least one of 
the RNA components by inserting a non-viral DNA segment 
in a region able to tolerate such insertion without disrupting 
RNA replication thereof; transcribing the modified cDNA, 
or, in the case of a multipartite virus, transcribing each 
cDNA corresponding to an RNA component of the multi- 
partite virus; substituting the modified cDNAfor its unmodi- 
fied counterpart in the transcription reaction; infecting virus- 
susceptible protoplasts, cells, tissues or whole organisms 
with transcribed RNA, or a mixture of RNAs, either in 
solution or encapsidated, of each viral component including 
the modified RNA comprising messenger-sense RNA con- 
taining an exogenous RNA segment. From this point, the 
steps to be followed will vary, depending on the type of 
material infected and the route of infection. Protoplasts, cells 
and tissues of plants can be propagated vegetatively, regen- 
erated to yield whole plants by means of any technique 
suitable to the particular plant variety infected, and trans- 
planted to the field. Whole plants can be infected in situ. 
Infected plants and plant cells can produce many copies per 
cell of the modified viral RNA containing the exogenous 
RNA segment. If desired and if suitably inserted, by means 
of principles and processes known in the art, the exogenous 
WA segment can be caused to carry out a function within 
FIG. 1 shows a map of EcoRI-cleaved pB3M1. 
FIG. 2 shows a 21 nucleotide mismatch primer used to 
prime synthesis of DNA from M13JB3ESl. 
FIG. 3 shows the insertion of the CAT gene in in-frame 
linkage with the initiation codon of the BMV coat protein 
gene. 
FIG. 4 shows the insertion of the CAT gene at the SalI site 
of pBRP1. 
FIG. 5 shows the construction of pB3DCP. 
FIG. 6 shows the production of CAT by protoplasts 
inoculated with transcripts constructed according to the 
invention. 
DETAILED DESCRIPTION OF THE 
INVENTION 
In order to facilitate understanding of the invention, 
certain terms used throughout are herein defined. 
RNA virus-The term as used herein means a virus whose 
genome is RNA in single-stranded form, the single strand 
being a (+) strand, or messenger-sense strand. Replication 
of the viral (+) strand in a virus-infected cell occurs by a 
process of direct RNA replication and is therefore distin- 
guishable from the replication mechanism of retroviruses 
which undergo an intermediate step of reverse transcrip- 
tion in the host cell. 
Cis-acting replication element-This term denotes that por- 
tion of the RNA genome of an RNA virus which must be 
present in cis, that is, present as par1 of each viral strand 
as a necessary condition for replication. Virus replication 
presumably depends upon the existence of one or more 
trans (diffusible) elements which interact with the cis- 
acting element to carry out RNA replication. While trans- 
acting elements are necessary for replication, they need 
not be present or coded for on the modified RNA provided 
they are made available within the infected cell by some 
other means. For example, in the case of a mulitpartite 
RNA virus, the trans-acting functions may be provided by 
other, unmodified components of the viral genome used to 
transform the cells simultaneously with the modified 
RNA. The target cell may also be modified in a previous 
step to provide constitutive expression of the trans-acting 
functions. The cis-acting replication element is composed 
of one or more segments of viral RNA which must be 
present on any RNA molecule that is to be replicated 
within a host cell by RNA replication. The segment will 
most likely be the 5' terminal portion of the viral RNA 
molecule, and may include other portions as well. The 
cis-acting element is therefore defined in functional terms: 
any modification which destroys the ability of the RNA to 
replicate in a cell known to contain the requisite trans- 
acting elements, is deemed to be a modification in the 5 
cis-acting replication element. Conversely, any modifica- 
tion, such as an insertion in a sequence region which is 
able to tolerate such insertion without disrupting replica- 
tion, is a modification outside the cis-acting replication 
element. As is demonstrated herein, using the example of 10 
BMV, substantial portions of an RNA virus molecule may 
be modified, by deletion, insertion, or by a combination of 
deletion and insertion, without disrupting replication. 
The term "derived from" is used to identify the viral source 
of an RNA segment which comprises part of the modified is 
RNA. For example, for the modified RNAs described 
herein, substantial portions thereof are derived from 
BMV. The manner of deriving, whether by direct recom- 
bination at the RNA level, by transcription or by reverse 
transcription does not matter for the purpose of the 20 
invention. Indeed, it is contemplated that modifications 
may be made within the cis-acting replication element and 
elsewhere for example to modify the rate or amount of 
replication that is obtained. In the case of modified RNAs 
exemplified herein, a transcription vector was employed 25 
which preserved the exact 5' terminal nucleotide sequence 
of viral RNA. However the use of such a vector in 
transcribing viral RNA from cDNA is not considered 
essential to the invention, although it will be preferred if 
preservation of the exact nucleotide sequence at the 5' end 30 
is desired. An RNA segment which has been derived from 
a given source virus may, but need not be, identical in 
sequence to that segment as it exists in the virus. It will 
be understood that a cis-acting replicating element 
derived from a given RNA virus may have minor modi- 35 
fications in the nucleotide sequence thereof without sub- 
stantially interfering with RNA replication. 
Exogenous RNA segment is a term used to describe a 
segment of RNA to be inserted into the virus RNA to be 
modified, the source of the exogenous RNA segment 40 
being different from the RNA virus itself. The source may 
be another virus, a living organism such as a plant, animal, 
bacteria, virus or fungus, the exogenous RNA may be a 
chemically synthesized RNA or it may be a combination 
of the foregoing. The exogenous RNA segment may 
provide any function which is appropriate and known to 
be provided by an RNA segment. Such functions include, 
but are not limited to, a coding function in which the RNA 
acts as a messenger RNA encoding a sequence which, 
translated by the host cell, results in synthesis of a peptide 
or protein having useful or desired properties; the RNA 
segment may also be structural, as for example in ribo- 
somal RNA, it may be regulatory, as for example with 
small nuclear RNAs or anti-sense RNA, or it may be 
catalytic. A particularly interesting function is provided 
by anti-sense RNA, sometimes termed (-) strand RNA, 
which is in fact a sequence complementary to another 
RNA sequence present in the target cell which can, 
through complementary base pairing, bind to and inhibit 
the function of the RNA in the target cell. 
Various aspects of the stages outlined in the Summary 
section can be modified as needed, depending upon specific 
aspects of the virus selected as the transforming agent and of 
the RNA segment to be inserted. For example, if the inserted 
gene is in the form of messenger-sense RNA to be directly 
translated by the transformed cell, the gene must be free of 
intervening, nontranslated sequences, such as introns. On 
360 
6 
the other hand, the inserted gene need not be a naturally 
occurring gene, but may be modified, a composite of more 
than one coding segment, or it may encode more than one 
protein. The RNA may also be modified by combining 
insertions and deletions in order to control the total length or 
other properties of the modified RNA molecule. As demon- 
strated in Example 5 ,  a substantial portion of the RNA3 of 
BMV can be deleted without significantly effecting its 
replication in cells containing normal RNAl and RNA2. The 
inserted non-viral gene may be either prokaryotic or eukary- 
otic in origin as long as it is in a form which can be directly 
translated by the translation machinery of the recipient cell. 
Eukaryotic genes containing introns within the coding 
sequence must therefore be inserted in the form of a cDNA 
copy of the eukaryotic messenger RNA encoding the gene. 
The inserted gene may contain its own translation start 
signals, for example, a ribosomal binding site and start 
(AUG) codon, or it may be inserted in a manner which takes 
advantage of one or more of these components preexisting 
in the viral RNA to be modified. Certain structural con- 
straints must be observed to preserve correct translation of 
the inserted sequence, according to principles well under- 
stood in the art. For example, if it is intended that the 
exogenous coding segment is to be combined with an 
endogenous coding segment, the coding sequence to be 
inserted must be inserted in reading frame phase therewith 
and in the same translational direction. The term "non-viral" 
is used herein in a special sense to include any RNA segment 
which is not normally contained within the virus whose 
modification is exploited for effecting gene transfer and is 
therefore used synonymously with "exogenous". Therefore, 
a gene derived from a different virus species than that 
modified is included within the meaning of the terms "non- 
viral" and "exogenous" for the purposes of describing the 
invention. For example, a non-viral gene as the term is used 
herein could include a gene derived from a bacterial virus, 
an animal virus, or a plant virus of a type distinguishable 
from the virus modified to effect transformation. In addition, 
a non-viral gene may be a structural gene derived from any 
prokaryotic or eukaryotic organism. It will be understood by 
those ordinarily skilled in the art that there may exist certain 
genes whose transfer does not result in obvious phenotypic 
modification of the recipient cell. Such may occur, for 
example, if the translation product of the non-viral gene is 
toxic to the host cell, is degraded or processed in a manner 
which renders it non-functional or possesses structural fea- 
tures which render it impossible for the host cell to translate 
in sufficient quantities to confer a detectable phenotype on 
the transformed cells. However, the invention does not 
depend upon any specific property of an RNA segment or 
gene being transferred. Therefore, the possible existence of 
RNA segments or genes which fail to confer a readily 
observable phenotypic trait on recipient cells or plants is 
irrelevant to the invention and in any case will be readily 
recognizable by those of ordinary skill in the art without 
undue experimentation. 
An exogenous RNA segment may be inserted at any 
convenient insertion site in any of the cDNA sequences 
corresponding to a viral RNA, or component RNA of a 
multipartite RNA virus, provided the insertion does not 
disrupt a sequence essential for replication of the RNA 
within the host cell. For example, for a virus whose coat 
protein is not essential for replication, an exogenous RNA 
segment may be inserted within or substituted for the region 
which normally codes for coat protein. As desired, regions 
which contribute to undesirable host cell responses may be 
deleted or inactivated, provided such changes do not 
5,500,360 
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adversely effect the ability of the RNA to be replicated in the from commercial sources and were used according to the 
host cell. For many single component and multiparlite RNA vendor's recommendations or other variations known to the 
viruses, a reduction in the rate of normal RNA replication is art. Reagents, buffers and culture conditions and reaction 
tolerable and will in some instances be preferred, since the conditions for various enzyme catalyzed reactions are also 
amount of RNA produced in a ~ ~ o r m a l  infection is more than 5 known to those in the art. Reference works containing such 
enough to saturate the nbosomes of the transformed cell. techniques include the following: R. WU, ed. 
The Process can be Out by (1979) Meth. Enzymol. 68; R. Wu et al., eds. (1983) Meth. 
any means whereby RN.4 can be introduced into cells, whole 
~ ~ ~ ~ ~ ~ l ,  100, 101; L. Grossman and K. Moldave, eds. 
plants, plant tissues Or protoplasts. can be infected (1980) Meth, Enzymol. 65; J. H. Miller (1972) Experiment's 
the RNA Or enca~sidated in a virus particle, except lo in Molecular Genetics; R. Davis et al, (1980) Advanced 
that the modified RNA containing a RNA Bacterial Genetics; R. F. Schleif and P. C. Wensink (1982) 
segment is substituted for its counterpart in a normal infec- 
tion. Any other suitable means for introducing RNA into Practical Methods in Molecular Biology; and T. Manniatis 
target cells such as microinjection may be used. In some et al. Molecuzar 
cases it may be preferable to include all of the nod Textual use of the name of a restriction endonuclease in 
components in addition to the modified component. M~~~ 15 isolation, e.g., "BclI" refers to use of that enzyme in an 
than one component may be modified in the mixture of enzymatic digestion, except in a diagram where it can refer 
transforming components. It will be understood that the to the site of a sequence susceptible to action of that enzyme, 
amounts of each infecting component must be sufficient to e.g., a restriction site. In the text, restriction sites are 
insure that an adequate number of cells receive at least one indicated by the additional use of the word "site", e.g., "BclI 
of each component in the mixture. Other variables of the 20 site". The additional use of the word "fragment", e.g., "BclI 
infection process, such as pretreatment of the recipients, fragment", indicates a linear double-stranded DNA molecule 
addition of components to enhance the efficiency of infec- having ends generated by action of the named enzyme (e.g., 
tion, use of encapsidated or unencapsidated RNA, are mat- a restriction fragment). A phrase such as "BclYSmaI frag- 
ters of choice which those of ordinary skill in the art will be ment" indicates that the restriction fragment was generated 
able to manipulate to achieve desired transformation effi- 25 by the action of two different enzymes, here BclI and SmaI, 
ciency in a given situation. For instance, the choice of the two ends resulting from the action of different enzymes. 
multipartite plant RNA virus to be modified to effect gene Note that the ends will have the characteristics of being 
transfer in a given plant variety will depend upon known either sticky (i.e., having a single strand of protrusion 
host range properties of multipartite RNA viruses. For capable of base-pairing with a complementary single- 
example, BMV infects a variety of grasses and their related 30 stranded oligonucleotide) or blunt (i.e., having no single- 
domesticated relatives including barley, wheat and maize. stranded protrusion) and that the specificity of a sticky end 
Plant cells which are infected in culture will normally will be determined by the sequence of nucleotides compris- 
remain transformed as the cells grow and divide since the ing the single-stranded protrusion which in turn is deter- 
RNA components are able to replicate and thus become mined by the specificity of the enzyme which produces it. 
distributed to daughter cells upon cell division. Plants regen- 35 All plasmids are designated by a sequence of letters and 
erated from phenotypically modified cells, tissues or proto- numbers prefaced by a lower case "p", for example, pPM1. 
plasts remain phenotypically modified. Similarly, plants Clones of complete BMV cDNA inserted in pPMl are 
transformed as seedlings remain transformed during growth. named by the format pBxPMy, where x equals 1, 2 or 3 
Timing of application of the transforming components will designating the BMV component cloned (i.e., from RNA1, 
be governed by the result which is intended and by varia- 40 2 or 3) and y is an arbitrary isolate number. Thus, the set of 
tions in susceptibility to the transforming components dur- three plasmids, pBlPM18, pB2PM25 and pB3PM1 contains 
ing various stages of plant growth. complete cDNA copies of BMV RNAs 1, 2 and 3, respec- 
Many plant RNA viruses are seed transmitted from one tively, and represent, as a set, the complete BMV genomc. 
generation to the next. This property can be exploited to Certain steps of cloning, selection and vector increase 
effect genotypic transformation of a plant. That is to say, the 45 employed strains of E. coli. While the strains used herein 
modified RNA remains transmissible from one generation to have been designated, there are many equivalent strains 
the next, most likely by replication in the cytoplasm, and available to the public which may be employed. The use of 
thereby becomes transmissible from one generation to the a particular microorganism as a substitute for a strain 
next, just as seed-borne virus infections are transmitted from designated herein is a matter of routine choice available to 
one generation to the next. 50 those of ordinary skill in the art, according to well-known 
The following examples illustrate the principles of the principles. 
invention as applied to modification of BMV RNA3 and the 
use of modified BMV RNA3 containing a gene coding for EXAMPLE 1 
chloramphenicol acetyl transferase (CAT) in the phenotypic 
transformation of barley protoplasts. For convenience, any 55 Infectivity of Transcribed BMV-cDNA 
modification to a viral RNA which includes the insertion of 
a nonviral ribonucleotide sequence, whether or not com- In Vitro Transcription. 
bined with a deletion of viral RNA will be designated by a Transcription reactions contained 25 mM Tris-HC1, pH 
prime symbol following the number designating the RNA. 8.015 mM MgClJl50 mM NaClIl mM dithiothreito1/200 
For example, modified RNA3 is termed RNA3', or more 60 @I each rATP, KTP, and rUTPl25 @I rGTP15OO pM 
generally, RNAn is designated RNAn'. m7GpppG (P-L Biochemicals)/plasmid DNA (0.1 pglpl ) 
The following examples utilize many techniques well Escherichia coli RNA polymerase (0.05 unitslpl) (Promega 
known and accessible to those skilled in the arts of molecu- Biotec, Madison, Wis.). Reactions were incubated 30 rnin- 
lar biology, cloning, plant cell biology, plant virology and utes at 37" C., by which time the rGTP was nearly 
plant tissue culture. Such methods are fully described in one 65 exhausted. Additional rGTP was added to 25 @I and incu- 
or more of the cited references if not described in detail bation continued a further 30 minutes. For uncapped tran- 
herein. Unless specified otherwise, enzymes were obtained scripts, m7GpppG was deleted, rGTP was increased to 200 
5,500,360 
9 10 
pM, the concentrations of DNA and polymerase were 
doubled. and incubation was carried out for I hour. Reac- TABLE 1-continued 
tions were stopped by addition of EDTA to 10 mM and either 
diluted directly in inoculation buffer or phenol-extracted 
before nucleic acid recovery by ethanol precipitation. In 5 
most experiments, plasmids representing all three BMV 
components were pooled and cleaved at unique EcoRI sites 
3 base pairs past the 3' tenninus of each BMV sequence 
before transcription. FIG. 1 shows a map of EcoRI-cleaved 
pB3M1. The maps for pPMl containing cDNA of RNAl or lo  
RNA2 are the same, except that the region labeled "BMV- 
cDNA" is cDNA of RNA-I or RNA-2. 
Infectivity Testing. 
Seven-day-old barley seedlings (Hordeum vulgare L. cv. . _ 
Morex) were dusted with carbokndum powder A d  inocu- 
lated with either virion RNA or in vitro transcription mixes 
in 50 mM Tris PO,, pH 8.01250 mM NaCl15 mM EDTAI 
Bentonite (5 mglrnl) (5); 15-30 plants in a single 14-cm- 
diameter pot were treated with the same inoculum, using 
10-30 pl per plant. Plants were scored for the presence of 
mosaic symptoms 7-14 days after inoculation. 
BMV Isolation. 
Fourteen days after inoculation, virus was isolated from 
barley plants as described by Shih, et al. (1972) J. Mol. Biol. 
64,353, with the substitution of chloroform for carbon 
tetrachloride and a second polyethylene glycol precipitation 
for differential centrifugation. Viral RNA was isolated by 
phenol extraction and ethanol precipitation. 
Infectivity Testing of BMV cDNA Clones and Their In Vitro 
Transcripts. 
Cloning of complete cDNA copies of all three BMV 
genetic components in a general transcription vector, pPM1, 
has been described by Ahlquist, P. and Janda, M. (1984) 
Mol. Cell. Biol. 4,2876. DNA from such clones can be 
cleaved with EcoRI (FIG. 1) and transcribed in vitro in the 
presence of a synthetic cap structure to produce complete 
RNA copies of the BMV components that have the same 
capped 5' ends as authentic BMV RNAs, and an additional 
6 7  non-viral nucleotides at their 3' ends. 
To test the infectivity of these cloned DNAs and their 
transcripts, three plasmids, pB 1 PM18, pB2PM25, and 
pB3PM1, were selected. The selected clones contain cDNA 
copies of BMV RNAs 1, 2, and 3, respectively, and repre- 
sent, as a set, the complete BMV genome. The natural isolate 
of BMV propagated in our laboratory is referred to by its 
usual designation of Russian strain. Mixtures of the EcoRI- 
cut M1 plasmids and their capped transcription products 
were inoculated onto barley plants in parallel with untran- 
scribed DNA from the same plasmids. As judged by the 
production of normal viral symptoms, the transcribed plas- 
mid mixture was infectious, while the untranscribed plasmid 
mixture was not (Table 1). 
TABLE 1 
Com~arison of infectivitv of EcoRI-cut M1 ~lasmids. 
transcribed EcoRI-cut ~i plasmids, and ~uss i an  strain 
BMV virion RNAs over a range of inoculum concentrations. 
Comparison of infectivity of EcoRI-cut M1 plasmids, 
transcribed EcoRI-cut M1 plasmids, and Russian strain 
BMV virion RNAs over a range of inoculum concentrations. 
Pot No. Inoculum, nglpl Plants with symptomsltotal 
5 4 7120 
6 0.4 0121 
Russian strain BMV virion RNA 
7 10 21122 
8 1 1412 1 
9 0.1 212 1 
Mock-inoculated 
In vitro transcription yields approximately 3 BMV tran- 
scripts per plasmid (Ahlquist and Janda, 1984). Total BMV 
transcript content of the inocula for pots 4-6 is thus approxi- 
mately 75, 7.5, and 0.75 nglpl, respectively. 
The effects of various alterations to the transcription 
protocol were examined to more clearly characterize the 
infectious entity observed in plasmid transcription mixes. 
Infectivity required transcription of clones representing all 
three BMV genetic components. Moreover, infectivity was 
sensitive to Hinfl before or to RNase A after transcription, 
but it was not significantly affected by RNase A before or 
Hinfl after transcription. HinfI cleaves at 8 sites within 
pPMl and at 15, 10, and 12 sites within BMV 1, 2, and 3 
cDNAs, respectively. These results confirm that the 
observed infectivity arises from the in vitro transcripts rather 
than directly from their DNA templates. In addition, when 
plasmids were either not cut or were cut with PstI before 
transcription (cleaving 2.7 kilobases rather than 7 bases 
downstream of the cDNA end), infection was not observed, 
suggesting that infectivity is affected by the structure of the 
transcript 3' end. Finally, if the cap analog was omitted 
during in vitro transcription, no infection was detected, even 
if inoculum concentration was increased 20-fold. 
Infectivity of RNA transcribed in vitro from EcoRI-cut 
M1 plasmids was clearly lower than that of authentic BMV 
RNA. The number of infected plants produced from a given 
weight of in vitro-transcribed RNA was similar to that 
produced from %oth that weight of authentic BMV RNA 
(Table 1). The presence of the plasmid DNA template in the 
inoculum was not responsible for this effect, as addition of 
the same plasmid DNA to authentic BMV RNA did not 
affect its infectivity. 
Correlation of Symptomology with BMV Replication. 
To establish that such symptoms accurately reflect BMV 
replication, several molecular tests were applied. Nitrocel- 
lulose dot blots of total RNA (described by Garger, S. J. et 
al. (1983) Plant Mol. Biol. Reporter 1,21) extracted from 
leaves of symptom-expressing and symptomless plants 
inoculated with either authentic BMV RNA or in vitro BMV 
transcripts were probed with 32P-labeled cloned BMV 
cDNA. In all cases, symptom-expressing leaves showed a 
uositive hybridization resDonse. and in all cases but one. 
. . 
pot NO. I~IOCUIU~, ng/d plants with symptoms~tota~ symptomless leaves gave a negative response. The one 
60 exception was from a plant that had been inoculated with in 
EcoRI-cut pBlPM18, pB2PM25, pB3PMl 
vitro transcripts and showed no visible symptoms but gave 
1 100 0121 a positive hybridization signal. 
2 10 0123 Virus isolated from ~ l an t s  infected with cDNA transcri~ts 
3 1 0122 is serologically identic'al to Russian strain BMV in douGe- 
Transcribed EcoRI-cut pBlPM18, pB2PM25, pB3PM1 65 diffusion tests with anti-BMV antisera. Phenol extraction of 
BMV isolated from transcript-infected plants releases four 
RNAs that comigrate with Russian strain virion RNAs, 
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hybridize to BMV-specific DNA probes, and are highly DNA sequences shown in FIG. 2 are plus (+) strands only, 
infectious in subsequent inoculations. Therefore, multipar- defined as equivalent (not complementary) to the RNA 
tite RNA plant virus infection can be derived solely from sequence of BMV-RNA. 
appropriately cloned viral cDNA by means of a simple Insertion of this PstI site was generally similar to the 
transcription step. 5 previously described insertion of a SmaI site adjacent to the 
lambda P, promoter (Ahlquist and Janda, 1984). First the 
EXAMPLE 2 0.9 kb SalI-EcoRI fragment of pB3PM1 (FIG. 1) was 
isolated from a low-melting point agarose gel and subcloned 
Construction and Replication of a Specific Deletion into SalI EcoRI cleaved M13mp9. Colorless recombinant 
in the BMV Coat Gene 10 plaques were selected on X-gal/IPTG plates and the inser- 
lion of BMV sequences verified b; dideoxynucleotide 
In the reference may be made to FIG. sequencing (Biggen et al, (1983) Proc. Nat. Acad, Sci. USA 1 for location of the relevant restriction sites. 80, 3963). A single clone, designated M131B3ES1, was 
Plasmid P B ~ P M ~  DNA (Ahlquist, P. and Janda, M. selected for further work. A 21 nucleotide mismatch primer 
(1984)) was cleaved with SalI and XbaI and treated with the 15 (FIG. 2) was chemically synthesized and purified and used 
Klenow fragment of DNA polymerase 1 to generate blunt to prime synthesis of 32~-labeled DNA from M13/B3ES1 
ends (Maniatis et A. (1982) Molecular Cloning: A Labors- ssDNA. After synthesis, the DNA was cleaved with AvaI at 
toV Manual. Cold Spring Harbor). The approximately 5.2 a site in the M13 vector distal to the primer and the major 
kb fragment was isolated from a low melting point (LMP) labelled DNA fragment, containing the mismatch primer at 
agarose gel (Sanger et al. (1980) J. Mol. Bid. 143,161), 20 its 5' end and BMV3 sequences interior, was purified on an 
recircularized by treatment with T4 DNA ligase, and trans- alkaline agarose low melting point gel (Maniatis et al., 
formed into competent E. coli JM101. RF DNA from 1982). A second strand of DNA was primed with a lac 
selected ampicillin resistant tranSf0rnlant~ Was digested reverse primer (Ahlquist and Jan&, 1984), the ds synthetic 
simultaneously with S d I  and EcoRI to confirm regeneration DNA cleaved with x b a ~  and the approximately 0.36 kb 
of the SalI site and deletion of the desired fragment. A single 25 &DNA fragment, containing the mismatch primer linked to 
tested clone, designated pB3DCP10, having the region of 3' BMV RNA3 sequences, isolated from a low melting point 
the coat gene from SalI to SbaI deleted, was selected for agarose gel. This fragment was then subcloned into XbaI- 
further work. SmaI cut M13mp19. Colorless recombinant plaques were 
EcoRI-digested pB3DCP10 was transcribed under cap- selected on X-gal/IPTG plates and the correct linkage of the 
ping conditions (Ahlquist and Janda, 1984) along with 30 PstI site to BMV cDNAconfirmed by dideoxy sequencing. 
EkoRI-digested pBlPM18 and pB2PM25 (Ahlquist and The 0.36 kb XbaI EcoRI fragment from a selected MI3 
Janda, 1984), and the transcripts were separated from the clone was recloned between the XbaI and SalI sites of 
plasmid DNA templates by LiCl precipitation (Baltimore PB3PM1, creating plasmid pB3RP1. The sequence of RNA 
(1966) J. Mol. Biol. 18, 421). Barley protoplasts were transcribed from PstI-cleaved pB3QP1 will be identical to 
prepared as described by Loesch-Fries and Hall (1980) J. 35 that of BMV RNA3 except that the 3'-terminal A will be 
Gen. Virol. 47, 323, and inoculated as described by Samac omitted. 
et al. (1983) Virology 131, 455, with the transcripts and 
incubated in the presence of [3H]uridine. Total nucleic acids EXAMPLE 4 
were extracted and analyzed on acrylamide-agarose gels as 
described by L~esch-Fries and Hall, 1980. The deleted 40 Insertion of a Bacterial Cloramphenicol Resistance 
RNA3 derived from pB3DCP10 was found to both replicate Gene in a BMV RNA3 Derivative and Expression 
and generate a deleted version of subgenomic RNA4. of a Functional Protein in Barley Cells 
(RNA4 is a subgenomic fragment of RNA3 produced during 
infection). This example demonstrates that a substantial Plasmid pB3RPl (Example 3) was cleaved with ~ a l I  and 
portion of RNA3 encoding coat protein can be deleted, 45 Xbd to delete most of the coat protein gene except for seven 
without preventing replication of viral RNAs. nucleotides at the beginning of the coat protein coding 
sequence including the AUG start codon, treated with the 
EXAMPLE 3 Klenow fragment of DNA polymerase I to produce blunt 
ends and the resulting larger DNA fragment isolated from a 
Insertion of a PstI Site at the 3' cDNA End of 50 
Plasmid pB3PM1 
Construction and use of transcribable BMV cDNA clones 
has been described before (Ahlquist et al. (1984) J. Mol. 
Biol. 172:369-383 and Ahlquist et al. (1984) Plant Mol. 55 
Biol. 3:37-44). To define the transcript 3' end, the originally 
described plasmids are first linearized before transcription 
by cleavage of an EcoRI site just outside the 3' end of BMV 
cDNA. However, such EkoRI cleavage results in addition of 
6-7 nonviral nucleotides to the transcript and is inconve- 60 
nient for transcription of BMV-linked foreign sequences 
which contain EcoRI site(s). To deal with both of these 
problems, a PstI site, i.e., a nucleotide sequence including a 
sequence recognized and cleaved by PstI endonuclease, was 
inserted immediately adjacent to the BMV cDNA in 65 
pB3PM2 to provide an alternate cleavage site. The steps in 
the construction can be followed by referring to FIG. 2. 
- - 
low melting point agarose gel. plasmid pBR325 (Bolivar, E 
(1978), Gene 4:121-136) was digested with TaqI, treated 
with Klenow polymerase and the 780 bp fragment contain- 
ing the chloramphenicol acyl transferase (CAT) gene was 
isolated. The 780 bp fragment isolated in this manner 
contained the entire CAT gene together with a short segment 
of pBR325 flanking the 5' end of the CAT gene coding 
sequence. The larger pB3W1 fragment and a three-fold 
molar excess of the CAT fragment were ligated with T4 
DNA ligase and transformed into E. coli JMlOl cells. 
Plasmid DNA from selected ampicillin-resistant transfor- 
mants was screened by double digestion with EcoRI and PstI 
and gel electrophoresis to confirm insertion of the CAT gene 
and to determine its orientation with respect to BMV3 
cDNA sequences. One plasmid, pB3CA42, containing the 
CAT gene coding sequences in the same orientation as the 
BMV3 coding sequences was selected for further work 
along with a plasmid, pB3CA52, with the CAT gene in the 
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reverse orientation. Insertion of the CAT gene in the positive EXAMPLE 5 
orientation, as in pB3CA42, results in in-frame linkage of 
the CAT coding sequences with the initiation codon of the Bal 31 Deletions in Plasmid pB3PMl 
BMV 'Oat gene ~ G '  3)' the 'Oat AUG plasmid pB3PMl DNA was cleaved with Cld, treated 
result in production of a fusion protein bearing with T4 DNA polymerase to produce blunt ends, ligated 
additional amino acids before the start of the native CAT to phosphorylated 12 bp synthetic BamHI linkers (Maniatis 
gene product. et al., 1982). After phenol/chloroform extraction and ethanol 
In a similar construction, diagrammed in FIG. 4, the same precipitation, the DNA was cleaved with 40 units BarnHI per 
CAT fragment was inserted at the SalI site of pBW1 by SalI lo pg linker for 16 hours at 37" C. After electrophoresis on 1% 
digestion followed by blunt ending with Klenow polymerase (wlv) low-melting point agarose the major ethidium bro- 
and ligation with DNA ligase. Two clones differing in the mide-staining band of DNA was eluted Ganger et al., 1980) 
orientation of the CAT gene were isolated, pB3CA31 with and recircularized by treatment with T4 DNA ligase at 
the CAT gene coding sequence oriented backwards from the approximately 2 ng DNA/d reaction, and transf~rmed into 
direction of transcription, and pB3CA21 with the CAT gene competent E. coli JM101. W DNA from randomly selected 
coding sequence oriented in the same direction as that of ampicillin-resistant transformants was digested simulta- 
transcription. FIG. 4 also shows the nucleotide sequence in neoudy with BamHI and EcORI and screened by gel 
the region of the junction point between BMV-derived and m~hOresis the presence of the BamH1 linker at 
bacterial-derived sequences, for pB3CA21. As a control, the desired point. A single clone, designated pB3C49, was 
SalI/XbaI deleted pB3 without an insertion was constructed, 20 selected for further work. 
designated pB3DCP, as shown in FIG. 5. The sequence in l2 C1al-cleaved pB3PM1 DNA was treated with l2 
the region of the subgenomic transcription start site and units of Bal31 at room temperature in a 180 pl reaction (Guo 
religation site is also shown in FIG. 5. As a further control, et al. (1983) Nucleic Acids Res. 11, 5521). 30 pl aliquots 
were removed 2, 4, 6, 8, 10 and 12 minutes after enzyme the CAT coding sequence was deleted from plasrnid 
addition. Nuclease digestion in each aliquot was terminated P~~~~~~ mG. 3, 
'leaving with Sail, "ling Out the 25 by addition of 25 @ of 40 mM EDTA and two successive 
recessed 3' ends with K1enow DNA P ~ ~ Y ~ ~ ~ ~ ~ ~  and deox~-  p h e n o l / c ~ o r o f o ~  extractions. The aliquots were pooled 
nucleotides, and religating the resultant blunt ends. and the DNA precipitated with ethanol. The DNA was 
PstI-cut pB3CA42 DNA and EcoRI-cut pBlPM18 and treated with the Klenow fragment of DNA polymerase I to 
pB2PM25 DNAs were transcribed, LiC1-precipitated and 30 generate blunt ends, and 12 bp synthetic BamHI linkers were 
used to inoculate protoplasts (Example 1). After 22 hours added (Maniatis et al, 1982). After phenoVchloroform 
incubation protoplasts were lysed by freezing and thawing extraction and ethanol precipitation, the DNA was treated 
and were found to contain CAT activity as assayed by with 50 units BamWpg linker and 2 units PstUpg plasmid 
standard methods (Herrera-Estrella et al. (1983) Nature 303, for 16 hours at 37" C. Products were run on a low melting 
209; Shaw, (1975) Methods Enzymol. 53,737). Cell lysates 35 point agarose gel and the high MW fraction containing the 
were incubated with [14C] chloramphenicol and, following approximately 4.2 kb C lmSt I  fragment of P B ~ P M ~  and its 
the published procedure, silica gel thin layer plates separat- Bal 31-deleted7 linker-ligated products was eluted and 
ing reactants and products were autoradiographed. The mixed with a molar ~XceSs of the approximately 1.5 kb 
results are shown in FIG. 6 .  Lanes marked Cm were loaded PstI-BamHI kagment of ~B3C49.  After ligation, DNA was 
with ["Q chloramphenicol only. CAT activity in other 40 transformed into competent E. coli JMlOl cells. RF DNA 
reactions is indicated by the appearance of acetylated was prepared from randomly-Selected ampicillin-resistant 
chlo-phenicol forms marked 1A-Cm (1-acetate) and transformants and was screened by double digestion with 
3A-Cm (3-acetate) in addition to the native form marked B"IHI and EcoRI followed by agarose gel electrophoresis. 
Cm. The lanes marked CAT-mi and CAT show the products Plasmids with deletions extending a variety of distances 
produced by authentic bacterial CAT in the presence of 45 frOm the initial ClaI site, within the 3a gene (FIG. I), of 
extracts from mock-inoculated protoplasts or buffer only. P B ~ P M ~  toward the I3coRI site were selected using this 
Panel A shows the products produced by extracts obtained data. Selected plasmids were cleaved with &JN and 
from protoplasts inoculated with transcripts from p~ I P M ~  8 scribed (Example 1) and the transcripts used to infect barley 
and pB2PM25, together with pB3CA21 (lane designated CA ~ro to~las t s  in the Presence of transcripts from EcoRI-cut 
21), pB3CA31 (lane designated CA 31), pB3CA42 (lane 50 plasmids pBlPM18 and pB2PM25. 
designated CA 42), pB3CA52 (lane designated CA 52), Using similar techniques a BarnHI linker was inserted in 
pB3CA61 (lane designated CA 61) or pB3PM1 (lane des- the SacI site of pB3PM1 and two further Bal 31 deletion 
ignated 3-1). In panel B the products obtained from extracts libraries were constructed, one with deletions extending 5' to 
of protoplasts inoculated with various combinations of the SacI site and one with deletions 3' to the SacI site. 
pBlPM18 (designated I), pB2PM25 (designated 2), 55 Transcripts from selected EcoRI-cut plasmids were tested in 
pB3PM1 (designated 3), and pB3CA42 (designated 3") are the presence of transcripts from EcoRI-cut pBlPM18 and 
shown. In parallel tests, mock-inoculated protoplasts and pB3PM25 in the barley protoplast system. Transcripts from 
protoplasts inoculated with transcripts from EcoRI-cut pB3PM1 derivatives with linker insertions in either the ClaI 
pBlPM18, EcoRI-cut pB2PM25 and either EcoRI-cut and SacI sites, and from derivatives with deletions extending 
pB3PM1 or PstI-cut pB3CA52 showed no detectable CAT 60 for up to several hundred bases from either site were found 
activity. The results shown in FIG. 6 demonstrate pheno- to replicate under such conditions. Substantial deletions 
typic transformation of the cells and further demonstrate that within the 3a gene and the coat protein gene can therefore be 
an RNA-3' containing an inserted nonviral coding segment, made, at least several hundred bases from either the ClaI site 
under appropriate conditions of infection, can effect such of the SacI site, without preventing replication of the deleted 
transformation. Only the combination of 1+2+ 3" provides 65 RNA. Such deletions provide room for large insertions while 
expression of the CAT gene, showing that this expression is still staying within the size constraints for packaging repli- 
dependent on viral RNA replication. cated RNA3' into virus particles. The remaining portion of 
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RNA, derived from RNA3, contains a cis-acting replication 2. The RNA of claim 1, wherein the exogenous RNA 
element of BMV RNA. Although the 3A gene and coat gene segment codes for a peptide or protein. 
were not required for RNA replication or for expression of 3. The RNA of claim 1 wherein the exogenous RNA 
the inserted CAT gene under the conditions of infection used segment comprises antisense RNA. 
in the example, either or both of these genes could, under 5 4. The RNA of claim 1 wherein the exogenous RNA 
other conditions, provide important secondary functions, for Segment structural RNA. 
example, by promoting systemic infection during transfer of 5. The wherein the exogenous RNA 
whole plants. Where deletion is not desired but the length of Segment comprises a RNA. 
the modified RNA exceeds the packaging constraints of the 6. The RNA of claim 1 wherein the exogenous RNA 
segment comprises RNA having catalytic properties. icosahedral BMV capsid, it may be possible to provide for 10 
,. The RNA molecule of claim wherein the cis-acting 
expression of the coat protein of a rod-shaped virus for replication element is derived from a multipartite plant 
encapsidating the modified RNA. virus. 
8. The RNA molecule of claim 1 wherein the cis-acting 
Discussion and Conclusions replication element is derived from tobacco mosaic virus. 
l5 9. The RNA molecule of claim 1 wherein the cis-acting 
The that replication element is derived from alfalfa mosaic virus. 
modifications, both deletions and insertions, can be made in The RNA molecule of claim wherein the cis-acting 
an RNA component a RNA virus replication element is derived from brome mosaic virus. 
preventing replication of viral RNA under appropriate con- 11. The RNA molecule of claim 1 encapsidated with viral 
ditions of infection. Genetic material inserted within a 20 coat m rote in. 
region of an RNA virus that is nonessential for RNA 
replication is translatable. In the case of BMV, substantial 
portions of RNA3 can be deleted without loss of the ability 
to replicate. Therefore any gene inserted within a nonessen- 
tial region of an RNA component of an RNA multipartite 25 
virus can be translated in the transformed cell, provided the 
gene has appropriate ribosome binding and translation ini- 
tiation signals at its 5' end. These signals can be provided by 
the virus or by the insert and the means for making trans- 
latable constructions is within the scope of capability of 30 
those ordinarily skilled in the art. 
While the foregoing principles were illustrated in the case 
of BMV RNA3, it is apparent that any component of any 
RNA virus is a candidate for modifications of the type 
illustrated. For example, an exogenous RNA segment could 35 
be inserted at any site of BMV RNA 1 or 2 which does not 
result in loss of ability to replicate. Similarly, the RNA 
components of other RNA viruses can be similarly manipu- 
lated, provided the insertions andlor deletions employed do 
not prevent replication of viral RNA. The two operating 40 
principles which permit the modification of a viral RNA 
component to make it a vector for carrying translatable 
genetic material into a host cell are: (1) cloning a cDNA of 
the RNA component into a transcription vector capable of 
transcribing replicatable RNA from viral cDNA, and (2) the 45 
identification of a region in one of the viral components that 
is nonessential for replication, into which a structural gene 
can be inserted. The modified RNA will therefore contain, at 
a minimum, a cis-acting replication element derived from an 
RNA virus and an inserted exogenous RNA segment. Fur- 50 
ther modifications and improvements following and 
embodying the teachings and disclosures herein are deemed 
to be within the scope of the invention, as set forth in the 
appended claims. 
We claim: 55 
1. A capped RNA molecule capable of infecting a host 
cell, which capped RNA molecule comprises a cis-acting 
replication element derived from a (+) strand RNA plant 
virus, which capped molecule has no extraneous nonviral 
sequences between the cap site and the 5' terminus of the 60 
viral sequence, and which capped RNA molecule further 
comprises an exogenous RNA segment capable of express- 
ing its function in a host cell in a region of said capped RNA 
molecule able to tolerate said segment without disrupting 
RNA replication of said capped RNA molecule, in the 65 
presence of trans-acting replication elements in said host 
cell. 
12. A DNA transcription vector comprising cDNA having 
one strand complementary to a capped RNA molecule 
capable of infecting a host cell, which capped RNA mol- 
ecule comprises a cis-acting replication element derived 
from a (+) strand RNA plant virus, which capped molecule 
has no extraneous nonviral sequences between the cap site 
and the 5' terminus of the viral sequence, and which capped 
RNA molecule further comprises an exogenous RNA seg- 
ment capable of expressing its function in a host cell in a 
region of said capped RNA molecule able to tolerate said 
segment without disrupting RNA replication of said capped 
RNA molecule, in the presence of trans-acting replication 
elements in said host cell. 
13. A method of modifying a host plant cell, genotypically 
or phenotypically, which method comprises introducing into 
the cell a capped RNA molecule capable of infecting said 
host cell, wherein the capped RNA molecule comprises a 
cis-acting replication element derived from a (+) strand 
RNA plant virus, wherein the capped RNA molecule has the 
same capped 5' end as said virus such that there are no 
extraneous nonviral sequences between the cap site and the 
5' terminus of the viral sequence, and wherein the capped 
RNA molecule further comprises an exogenous RNA seg- 
ment in a region of said capped RNA molecule able to 
tolerate said segment without disrupting RNA replication of 
said capped RNA molecule in the presence of trans-acting 
replication elements in said host cell, whereby the exog- 
enous RNA segment confers a detectable trait in the host 
cell, thereby modifying said host cell. 
14. The method of claim 13 wherein the exogenous RNA 
molecule codes for a peptide or protein. 
15. The method of claim 13 wherein the exogenous RNA 
segment comprises antisense RNA. 
16. The method of claim 13 wherein the exogenous RNA 
segment comprises structural RNA. 
17. The method of claim 13 wherein the exogenous RNA 
segment comprises a regulatory RNA. 
18. The method of claim 13 wherein the exogenous RNA 
segment comprises RNA having catalytic properties. 
19. The method of claim 13 wherein the cis-acting rep- 
lication element is derived from a multipartite plant virus. 
20. The method of claim 13 wherein the cis-acting rep- 
lication element is derived from tobacco mosaic virus. 
21. The method of claim 13 wherein the cis-acting rep- 
lication element is derived from alfalfa mosaic virus. 
22. The method of claim 13 wherein the cis-acting rep- 
lication element is derived from brome mosaic virus. 

